Hostname: page-component-78c5997874-4rdpn Total loading time: 0 Render date: 2024-11-16T15:29:10.636Z Has data issue: false hasContentIssue false
  • English
  • Français

Ginkgo biloba leaf extract (EGb 761®) and its specific acylated flavonol constituents increase dopamine and acetylcholine levels in the rat medial prefrontal cortex: possible implications for the cognitive enhancing properties of EGb 761®

Published online by Cambridge University Press:  12 July 2012

J. Kehr ,
S. Yoshitake ,
S. Ijiri ,
E. Koch ,
M. Nöldner  and
T. Yoshitake
J. Kehr*
Affiliation:
Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden Pronexus Analytical AB, Stockholm, Sweden
S. Yoshitake
Affiliation:
Pronexus Analytical AB, Stockholm, Sweden
S. Ijiri
Affiliation:
School of Pharmacy, International University of Health and Welfare, Tochigi, Japan
E. Koch
Affiliation:
Preclinical Research, Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe, Germany
M. Nöldner
Affiliation:
Preclinical Research, Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe, Germany
T. Yoshitake
Affiliation:
Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden
*
Correspondence should be addressed to: Dr. Jan Kehr, Pronexus Analytical AB, Karolinska Institutet Science Park, Fogdevreten 2a, 171 77 Stockholm, Sweden. Phone: +46 8 403 90125; Fax: +46 8 5248 7234. Email: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Experimental and clinical data suggest that the Ginkgo biloba standardized extract EGb 761® exerts beneficial effects in conditions which are associated with impaired cognitive function. However, the neurochemical correlates of these memory enhancing effects are not yet fully clarified. The aim of this study was to examine the effect of repeated oral administration of EGb 761® and some of its characteristic constituents on extracellular levels of dopamine (DA), noradrenaline (NA), serotonin (5-HT), acetylcholine (ACh) and the metabolites 3,4-dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA) and 5-hydroxyindoleacetic acid (5-HIAA) in the medial prefrontal cortex (mPFC) of awake rats by use of in vivo microdialysis technique.

Subacute (14 days, once daily), but not acute, oral treatment with EGb 761® (100 and 300 mg/kg) or the flavonoid fraction, which represents about 24% of the whole extract caused a significant and dose-dependent increase in extracellular DA levels in the mPFC. Repeated administration of EGb 761® also caused a modest but significant increase in the NA levels, whereas the concentrations of 5-HT and those of the metabolites DOPAC, HVA and 5-HIAA were not affected. The same treatment regimen was used in a subsequent study with the aim of investigating the effects of two Ginkgo-specific acylated flavonols, 3-O-(2’’-O-(6’’’-O-(p-hydroxy-trans-cinnamoyl)-β-D-glucosyl)-α-L-rhamnosyl)quercetin (Q-ag) and 3-O-(2’’-O-(6’’’-O-(p-hydroxy-trans-cinnamoyl)-β-D-glucosyl)-α-L-rhamnosyl)kaempferol (K-ag). Both compounds together represent about 4.5% of the whole extract. Repeated oral treatment with Q-ag (10 mg/kg) for 14 days caused a significant increase in extracellular DA levels of 159% and extracellular acetylcholine (ACh) levels of 151% compared to controls. Similarly, administration of K-ag (10 mg/kg) induced a significant rise of DA levels to 142% and ACh levels to 165% of controls, whereas treatment with isorhamnetin, an O-methylated aglycon component of EGb 761® flavonol glycosides had no effect. None of the tested flavonoids had a significant effect on extracellular DOPAC and HVA levels.

The present findings provide evidence that the subacute treatment with EGb 761® and its flavonol constituents increases DA and ACh release in the rat mPFC, and suggest that the two Ginkgo-specific acylated flavonol glycosides Q-ag and K-ag are active constituents contributing to these effects. As seen for isorhamnetin, the effect on neurotransmitter levels seems not to be a general effect of flavonols but rather to be a specific action of acylated flavonol glycosides which are present in EGb 761®. The direct involvement of these two flavonol derivatives in the increase of dopaminergic and cholinergic neurotransmission in the prefrontal cortex may be one of the underlying mechanisms behind the reported effects of EGb 761® on the improvement of cognitive function.

Keywords

Ginkgo bilobaneurotransmitter releasemicrodialysisrat
Type
Research Article
Information
International Psychogeriatrics , Volume 24 , Supplement S1: The aging brain: current concepts, intervention strategies and the role of Ginkgo biloba extract EGb 761 , August 2012 , pp. S25 - S34
Copyright
Copyright © International Psychogeriatric Association 2012

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Abdel-Kader, R. et al. (2007). Stabilization of mitochondrial function by Ginkgo biloba extract (EGb 761). Pharmacological Research, 56, 493–502.CrossRefGoogle ScholarPubMed
Ahlemeyer, B. and Krieglstein, J. (2003). Neuroprotective effects of Ginkgo biloba extract. Cellular and Molecular Life Sciences, 60, 1779–1792.CrossRefGoogle ScholarPubMed
Ahmad, M. et al. (2005). Ginkgo biloba affords dose-dependent protection against 6-hydroxydopamine-induced parkinsonism in rats: neurobehavioural, neurochemical and immunohistochemical evidences. Journal of Neurochemistry, 93, 94–104.CrossRefGoogle ScholarPubMed
Andrieu, S. et al. (2003). EPIDOS study. Association of Alzheimer's disease onset with ginkgo biloba and other symptomatic cognitive treatments in a population of women aged 75 years and older from the EPIDOS study. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences, 58, 372–377.CrossRefGoogle Scholar
Andrieu, S. and GuidAge study GROUP. (2008). GuidAge study: a 5-year double blind, randomised trial of EGb 761® for the prevention of Alzheimer's disease in elderly subjects with memory complaints. i. rationale, design and baseline data. Current Alzheimer Research, 5, 406–415.CrossRefGoogle ScholarPubMed
Bachinskaya, N., Hoerr, R. and Ihl, R. (2011). Alleviating neuropsychiatric symptoms in dementia: the effects of Ginkgo biloba extract EGb 761®: findings from a randomized controlled trial. Neuropsychiatric Disease and Treatment, 7, 209–215.Google ScholarPubMed
Bartus, R. T., Dean, R. L. III, Beer, B. and Lippa, A. S. (1982). The cholinergic hypothesis of geriatric memory dysfunction. Science, 217, 408–414.CrossRefGoogle ScholarPubMed
Bedir, E. et al. (2002). Biologically active secondary metabolites from Ginkgo biloba. Journa of Agricultural and Food Chemistry, 50, 3150–3155.CrossRefGoogle ScholarPubMed
Blecharz-Klin, K., Piechal, A., Joniec, I., Pyrzanowska, J. and Widy-Tyszkiewicz, E. (2009). Pharmacological and biochemical effects of Ginkgo biloba extract on learning, memory consolidation and motor activity in old rats. Acta Neurobiologiae Experimentalis (Warsaw), 69, 217–231.CrossRefGoogle ScholarPubMed
Brunello, N., Racagni, G., Clostre, F., Drieu, K. and Braquet, P. (1985). Effects of an extract of Ginkgo biloba on noradrenergic systems of rat cerebral cortex. Pharmacological Research Communications, 17, 1063–1072.CrossRefGoogle ScholarPubMed
Castner, S. A. and Goldman-Rakic, P. S. (2004). Enhancement of working memory in aged monkeys by a sensitizing regimen of dopamine D1 receptor stimulation. Journal of Neuroscience, 24, 1446–1450.CrossRefGoogle ScholarPubMed
Chan, P. C., Xia, Q. and Fu, P. P. (2007). Ginkgo biloba leave extract: biological, medicinal, and toxicological effects. Journal of Environmental Science and Health, Part C: Environmental Carcinogensis and Ecotoxicology Reviews, 25, 211–244.CrossRefGoogle ScholarPubMed
Coyle, J. T., Price, D. L. and DeLong, M. R. (1983). Alzheimer's disease: a disorder of cortical cholinergic innervation. Science, 219, 1184–1190.CrossRefGoogle ScholarPubMed
Dartigues, JF, Carcaillon, L, Helmer, C, Lechevallier, N, Lafuma, A, Khoshnood, B (2007). Vasodilators and Nootropics as Predictors of Dementia and Mortality in the PAQUID Cohort. J Am Geriatr Soc 55: 395–399.CrossRefGoogle ScholarPubMed
DeFeudis, F. V. (2003). A brief history of EGb 761® and its therapeutic uses. Pharmacopsychiatry, 36 (Suppl 1), S2–7.Google ScholarPubMed
DeFeudis, F. V. and Drieu, K. (2000). Ginkgo biloba extract (EGb 761®) and CNS functions: basic studies and clinical applications. Current Drug Targets, 1, 25–58.CrossRefGoogle ScholarPubMed
DeKosky, S. T. et al. (2008). Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA, 300, 2253–2262.CrossRefGoogle ScholarPubMed
Dodge, H. H., Zitzelberger, T., Oken, B. S., Howieson, D. and Kaye, J. (2008). A randomized placebo-controlled trial of Ginkgo biloba for the prevention of cognitive decline. Neurology, 70, 1809–1817.CrossRefGoogle ScholarPubMed
Fehske, C. J., Leuner, K. and Müller, W. E. (2009). Ginkgo biloba extract (EGb761®) influences monoaminergic neurotransmission via inhibition of NE uptake, but not MAO activity after chronic treatment. Pharmacological Research, 60, 68–73.CrossRefGoogle Scholar
Grass-Kapanke, B., Busmane, A., Lasmanis, A., Hoerr, A. and Kaschel, R. (2011). Effects of Ginkgo biloba special extract EGb 761® in very mild cognitive impairment (vMCI). Neuroscience & Medicine, 2, 48–56.CrossRefGoogle Scholar
Goldman-Rakic, P. S. (1995). Cellular basis of working memory. Neuron, 14, 477–485.CrossRefGoogle ScholarPubMed
Goldman-Rakic, P. S., Muly, E. C. III and Williams, G. V. (2000). D(1) receptors in prefrontal cells and circuits. Brain Research. Brain Research Reviews, 31, 295–301.CrossRefGoogle ScholarPubMed
Hasler, A. (1993). Ginkgo, ein modernes Phytopharmakon? Schweizerische Apotheker Zeitung, 131, 315–316.Google Scholar
Hasler, A. (2000). Chemical constituents of Ginkgo biloba. In van Beek, T. A. (ed.), Ginkgo biloba (pp. 109–142). The Netherlands: Harwood Academic.Google Scholar
Hertel, P., Nomikos, G. G. and Svensson, T. H. (1999). Idazoxan preferentially increases dopamine output in the rat medial prefrontal cortex at the nerve terminal level. European Journal of Pharmacology, 371, 153–158.CrossRefGoogle ScholarPubMed
Huguet, F. and Tarrade, T. (1992). Alpha 2-adrenoceptor changes during cerebral ageing. The effect of Ginkgo biloba extract. Journal of Pharmacy and Pharmacology, 44, 24–27.CrossRefGoogle ScholarPubMed
Huguet, F., Drieu, K. and Piriou, A. (1994). Decreased cerebral 5-HT1A receptors during ageing: reversal by Ginkgo biloba extract (EGb 761®). Journal of Pharmacy and Pharmacology, 46, 316–318.CrossRefGoogle ScholarPubMed
Ihl, R. et al. (2011). Efficacy and safety of a once-daily formulation of Ginkgo biloba extract EGb 761® in dementia with neuropsychiatric features: a randomized controlled trial. International Journal of Geriatric Psychiatry, 26, 1186–1194.CrossRefGoogle ScholarPubMed
IQWiG Institute for Quality and Efficacy in Health Care (2008). Ginkgo in Alzheimer's disease. Executive Summary. Commission No. A05-19B. Available at: https://www.iqwig.de/download/A05-19B_Abschlussbericht_Ginkgohaltige_Praeparate_bei_Alzheimer_Demenz.pdf (last accessed 27 Sept. 2011)Google Scholar
Jerant, A., Chapman, B., Duberstein, P., Robbins, J. and Franks, P. (2011). Personality and medication non-adherence among older adults enrolled in a six-year trial. British Journal of Health Psychology, 16, 151–169.CrossRefGoogle Scholar
Kaschel, R. (2011). Specific memory effects of Ginkgo biloba extract EGb 761® in middle-aged healthy volunteers. Phytomedicine, 18, 1202–1207.CrossRefGoogle ScholarPubMed
Kim, D. H., Maneen, M. J. and Stahl, S. M. (2009). Building a better antipsychotic: receptor targets for the treatment of multiple symptom dimensions of schizophrenia. Neurotherapeutics, 6, 78–85.CrossRefGoogle ScholarPubMed
Meltzer, H. Y. and Huang, M. (2008). In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems. Progress in Brain Research, 172, 177–197.CrossRefGoogle ScholarPubMed
Müller, W. E. and Chatterjee, S. S. (2003). Cognitive and other behavioral effects of EGb 761® in animal models. Pharmacopsychiatry, 36 (Suppl. 1), S24–S31.Google ScholarPubMed
O'Brien, J. T. and Burns, A.on behalf of the BAP Dementia Consensus Group (2011). Clinical practice with anti-dementia drugs: a revised (second) consensus statement from the British Association for Psychopharmacology. Journal of Psychopharmacology, 25, 997–1019.CrossRefGoogle ScholarPubMed
Pardon, M. C., Joubert, C., Perez-Diaz, F., Christen, Y., Launay, J. M. and Cohen-Salmon, C. (2000). In vivo regulation of cerebral monoamine oxidase activity in senescent controls and chronically stressed mice by long-term treatment with Ginkgo biloba extract (EGb 761®). Mechanisms of Ageing and Development, 113, 157–168.CrossRefGoogle ScholarPubMed
Paspalas, C. D. and Goldman-Rakic, P. S. (2005). Presynaptic D1 dopamine receptors in primate prefrontal cortex: target-specific expression in the glutamatergic synapse. Journal of Neuroscience, 25, 1260–1267.CrossRefGoogle ScholarPubMed
Rojas, P., Serrano-García, N., Mares-Sámano, J. J., Medina-Campos, O. N., Pedraza-Chaverri, J. and Ögren, S. O. (2008). EGb 761® protects against nigrostriatal dopaminergic neurotoxicity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice: role of oxidative stress. European Journal of Neuroscience, 28, 41–50.CrossRefGoogle ScholarPubMed
Satvat, E. and Mallet, P. E. (2009). Chronic administration of a Ginkgo biloba leaf extract facilitates acquisition but not performance of a working memory task. Psychopharmacology (Berlin), 202, 173–185.CrossRefGoogle Scholar
Shah, Z. A., Sharma, P. and Vohora, S. B. (2003). Ginkgo biloba normalises stress-elevated alterations in brain catecholamines, serotonin and plasma corticosterone levels. European Neuropsychopharmacology, 13, 321–325.CrossRefGoogle ScholarPubMed
Shin, J. C., Chen, K., Ridd, M. J. and Seif, I. (2000). Ginkgo biloba abolishes aggression in mice lacking MAO A. Antioxidants & Redox Signaling, 2, 467–471.Google Scholar
Singh, V., Singh, S. P. and Chan, K. (2010). Review and meta-analysis of usage of ginkgo as an adjunct therapy in chronic schizophrenia. International Journal of Neuropsychopharmacology, 13, 257–271.CrossRefGoogle ScholarPubMed
Stackman, R. W., Eckenstein, F., Frei, B., Kulhanek, D., Nowlin, J, and Quinn, J. F. (2003). Prevention of age-related spatial memory deficits in a transgenic mouse model of Alzheimer's disease by chronic Ginkgo biloba treatment. Experimental Neurology, 184, 510–520.CrossRefGoogle Scholar
Taylor, J. E. (1986). Neuromediator binding to receptors in the rat brain. The effect of chronic administration of Ginkgo biloba extract. (French). La Presse Médicale, 15, 1491–1493.Google Scholar
Tellez, S., Colpaert, F. and Marien, M. (1999). Alpha2-adrenoceptor modulation of cortical acetylcholine release in vivo. Neuroscience, 89, 1041–1050.CrossRefGoogle ScholarPubMed
Terry, A. V. Jr. (2008). Role of the central cholinergic system in the therapeutics of schizophrenia. Current Neuropharmacology, 6, 286–292.CrossRefGoogle ScholarPubMed
Terry, A. V. Jr. and Buccafusco, J. J. (2003). The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: recent challenges and their implications for novel drug development. Journal of Pharmacology and Experimental Therapeutics, 306, 821–827.CrossRefGoogle ScholarPubMed
Thomas, D. N., Nutt, D. J. and Holman, R. B. (1998). Sertraline, a selective serotonin reuptake inhibitor modulates extracellular noradrenaline in the rat frontal cortex. Journal of Psychopharmacology, 12, 366–370.CrossRefGoogle ScholarPubMed
Vellas, B. and Guidage Study Group. (2010). Results of GuidAge: a 5-year placebo-controlled study of the efficacy of EGb 761(R) 120mg to prevent or delay Alzheimer's dementia onset in elderly subjects with memory complaint. Journal of Nutrition Health and Aging, 14 (Suppl. 2), S23–S23.Google Scholar
Viskupicova, J., Ondrejovic, M. and Sturdik, E. (2009). The potential and practical applications of acylated flavonoids. Pharmazie, 64, 355–360.Google ScholarPubMed
Wang, Y., Wang, L., Wu, J. and Cai, J. (2006). The in vivo synaptic plasticity mechanism of EGb 761®-induced enhancement of spatial learning and memory in aged rats. British Journal of Pharmacology, 148, 147–153.CrossRefGoogle ScholarPubMed
Wang, B. S. et al. (2010). Effectiveness of sstandardized Ginkgo biloba extract on cognitive symptoms of dementia with a six-month treatment: a bivariate random effect meta-analysis. Pharmacopsychiatry, 43, 86–91.CrossRefGoogle Scholar
Weikop, P., Kehr, J. and Scheel-Krüger, J. (2004). The role of alpha1- and alpha2-adrenoreceptors on venlafaxine-induced elevation of extracellular serotonin, noradrenaline and dopamine levels in the rat prefrontal cortex and hippocampus. Journal of Psychopharmacology, 18, 395–403.CrossRefGoogle ScholarPubMed
Weinmann, S., Roll, S., Schwarzbach, C., Vauth, C. and Willich, S. N. (2010). Effects of Ginkgo biloba in dementia: systematic review and meta-analysis. BMC Geriatrics, 10, 14. http://www.biomedcentral.com/1471-2318/10/14.CrossRefGoogle ScholarPubMed
White, H. L., Scates, P. W. and Cooper, B. R. (1996). Extracts of Ginkgo biloba leaves inhibit monoamine oxidase. Life Sciences, 58, 1315–1321.CrossRefGoogle ScholarPubMed
Yoshitake, T., Kehr, J., Yoshitake, S., Fujino, K., Nohta, H. and Yamaguchi, M. (2004). Determination of serotonin, noradrenaline, dopamine and their metabolites in rat brain extracts and microdialysis samples by column liquid chromatography with fluorescence detection following derivatization with benzylamine and 1,2-diphenylethylenediamine.Journal of Chromatography: B, Analytical Technologies in the Biomedical and Life Sciences, 807, 177–183.Google ScholarPubMed
Yoshitake, T., Yoshitake, S. and Kehr, J. (2010). The Ginkgo biloba extract EGb 761(R) and its main constituent flavonoids and ginkgolides increase extracellular dopamine levels in the rat prefrontal cortex. British Journal of Pharmacology, 159, 659–668.CrossRefGoogle ScholarPubMed
Zhang, W. F., Tan, Y. L., Zhang, X. Y., Chan, R. C., Wu, H. R. and Zhou, D. F. (2011). Extract of Ginkgo biloba treatment for tardive dyskinesia in schizophrenia: a randomized, double-blind, placebo-controlled trial. Journal of Clinical Psychiatry, 72, 615–621.CrossRefGoogle ScholarPubMed